跳到正文
原文
MedPage Today·· 17 天前精选AI 评分85

降阶梯治疗 HPV 相关头颈部癌症获得长期支持数据

De-Escalated Treatment for HPV-Related Throat Cancer Gets Long-Term Supporting Data

AI 导读

一项前瞻性研究显示,降阶梯治疗 HPV 阳性头颈部癌症在 5 年随访中实现 94% 无证据疾病生存率和 90.6% 总生存率。治疗包括 30 Gy 选择性淋巴结照射和低风险区域照射省略,未见失败。尽管需要多中心 III 期试验确认,但结果支持降阶梯治疗。

推荐理由

长期随访显示,降阶梯治疗在 HPV 阳性头颈部癌症中实现高生存率和无病生存率。

正文

— More than 90% of patients alive without evidence of disease at 5 years

November 3, 2026 • 4 min read

  • De-escalated treatment for HPV-positive oropharyngeal cancer achieved durable cancer control in over 90% of patients.
  • Treatment reduced elective nodal radiation to 30 Gy and omitted low-risk nodal regions without failures.
  • The results add to existing evidence supporting de-escalation for HPV-positive oropharyngeal cancer but this particular regimen still requires confirmation in a multicenter phase III trial.

Reduced-intensity treatment for human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) led to durable cancer control in more than 90% of patients, long-term follow-up from a prospective study showed.

After a median follow-up of 5 years, 94% of patients had no evidence of disease and 90.6% were alive at last follow-up after de-escalated elective nodal irradiation (ENI) during definitive concurrent chemoradiation (CRT). Five-year locoregional control, distant metastasis-free survival (DMFS), and overall survival (OS) exceeded 90%. All but one patient with locoregional failure had recurrences in areas with known residual macroscopic disease. No treatment failures occurred in nodal basins that were omitted from treatment.

De-escalation came in the form of 30-Gy ENI instead of the usual 50-60 Gy dose and omission of low-risk nodal basins, reported Nancy Y. Lee, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues in JAMA Oncology.

"These outcomes were attained across the spectrum of T- and N-stage groups and smoking histories among patients predominantly treated with concurrent platinum-based chemoradiosensitization," the authors noted. "The systematic omission of uninvolved nodal levels IB/V did not result in failures in those areas and provides a simple class solution to reducing irradiated volume and toxic effects. The 30-Gy ENI dose remains the lowest among published approaches, is tailored to HPV-associated disease, and results in the lowest reported gastrostomy tube insertion rate."

"Although low-dose ENI without concurrent chemotherapy has been investigated, recent phase III randomized trials have demonstrated the superiority of concurrent platinum-based chemotherapy for achieving cure in HPV-associated OPC, underscoring the importance of de-escalating ENI within an optimally curative paradigm for HPV-associated OPC," they wrote.

The study showed that focusing on radiation dose is not the only strategy to de-escalate treatment for HPV-associated OPC, said David Sher, MD, of UT Southwestern Medical Center in Dallas, who was not involved in the study.

"While we often focus on the total dose delivered to visible cancer, in actuality, ENI is responsible for a substantial amount of normal tissue irradiation and dose to critical normal structures, such as the salivary glands and swallowing structures," Sher, an expert for the American Society for Radiation Oncology, told MedPage Today. "There has been a progressive recognition that ENI dose can be a significant contributor to quality-of-life outcomes, and there are several studies, both prospective and retrospective, that have shown that the standard dose of 50 Gy can be substantially lowered."

"[The] degree of success is remarkable given the extent of dose reduction, and it is exciting to see such superb outcomes," he added. "Although we do not have quality-of-life data from this study, prior reports were also very favorable."

Providing additional context for the study results, Sher noted that all patients underwent PET-CT imaging and the vast majority had MRI as well. Such advanced imaging may play a key role in identifying smaller lymph nodes that might harbor cancer and require higher radiation doses. Additionally, all the patients received cisplatin-containing chemotherapy, and HPV-associated OPC is cisplatin sensitive. Also, the authors did not report how many "equivocal" lymph nodes were treated with a higher radiation dose.

Results of the current study add to those of a previous phase III trial that used a slightly higher nodal irradiation dose, he added.

"All of this work strongly suggests we are delivering ENI doses that are far too high, and we need to be more aggressive in reducing the acute and long-term side-effect burden of our treatments while preserving oncologic efficacy," said Sher. "For such a result to become a true standard of care, though, we do need a phase III randomized study to confirm non-inferiority in a multi-institutional setting, and hopefully such a trial can be available soon to patients and our community."

Lee and colleagues previously reported 2-year outcomes with the de-escalation strategy, showing good locoregional control and survival with "excellent" quality of life. The current report aimed to establish the durability of the strategy, as assessed after a median follow-up of 5 years.

The analysis involved 276 patients treated with intensity-modulated radiotherapy (n=256) or intensity-modulated proton therapy (n=20). Treated nodal and subclinical regions received 30 Gy in 15 fractions and a sequential boost of 40 Gy in 20 fractions.

The 5-year results showed that 260 patients had no evidence of disease at 5 years and 250 were alive at last follow-up. Five-year outcomes were:

  • Locoregional control: 97.0%
  • OS: 90.8%
  • Progression-free survival: 85.9%
  • DMFS: 91.2%

A single elective nodal failure occurred 6 months after concurrent CRT in a contralateral indeterminate lymph node present at baseline and treated with 30 Gy, the authors reported. The last regional failure occurred 18 months post-treatment. Distant-only recurrences occurred in 23 patients. At last follow-up, 12 of the patients remained alive with no evidence of disease, and one remained alive with disease.

来源:MedPage Today · medpagetoday.com